Immunomodulatory Effects of Granulocyte and Monocyte Adsorption Apheresis as a Treatment for Patients with Ulcerative Colitis
- 117 Downloads
Our aim was to understand the mechanism of immunological changes associated with the use of an adsorptive-type extracorporeal device (Adacolumn) that has been developed for selective adsorption of granulocytes and monocytes/macrophages from peripheral blood of patients with active ulcerative colitis. The column is filled with carriers (G-1 beads) that have a diameter of 2 mm and are made of cellulose diacetate. In peripheral blood treated with the G-1 beads or peripheral blood from patients with active ulcerative colitis following granulocyte and monocyte adsorption apheresis, a significant suppression of proinflammatory cytokines (tissue necrosis factor-α, interleukin-1β, interleukin-6, and interleukin-8) production by leukocytes, neutrophil chemotaxis, down-regulation of leukocyte adhesion molecule (L-selectin) and neutrophil adhesion to interleukin-1β-activated endothelial cells were observed. Furthermore, after granulocyte adsorption therapy, the number of CD10-negative premature granulocytes increased, indicating increased turnover of these cells in the circulation. Our observations suggest that selective granulocyte and monocyte adsorption is associated with modified peripheral blood leukocyte function favorable to patients with ulcerative colitis and possibly other autoimmune disorders which reflect leukocyte hyperactivity.
Unable to display preview. Download preview PDF.
- 1.Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR: Safety and efficacy of granulocyte and monocyte apheresis in patients with active ulcerative colitis: An open-label pilot multicenter study. J Clin Apher 16:1–9, 2001Google Scholar
- 2.D'Arrigo C, Candal-Couto JJ, Greer M, Veale DJ, Woof JM: Human neutrophil Fc receptor mediated adhesion under flow: A hallow fiber model of intravascular arrest. Clin Exp Immunol 100:173–179, 1994Google Scholar
- 5.Grisham MB, Granger N: mechanisms of neutrophil-mediated tissue injury. In Inflammatory Bowel Disease. RP MacDermott, WF Stenson (eds). New York, Elsevier, 1992, pp 225–239Google Scholar
- 6.Yamada T, Volkmer C, Grisham MB: Antioxidant properties of 5-aminosalicylic acid: Potential mechanism for its antiinflammatory activity. In Trends in Inflammatory Bowel Disease Therapy. CN Williams (ed). Boston, Kluwer Academic Publishers, 1990, pp 73–84Google Scholar
- 13.Wengrower D, Liakim R, Karmeli F, Razin E, Rachmilewitz D: Pathogenesis of ulcerative colitis (UC): Enhanced formation of inositol phosphate (IP) and platelet activating factor (PAF). Gastroenterology 92:1691–1695, 1987Google Scholar
- 15.Featherstone C: Anti-integrin drugs developed to treat inflammation. The Lancet 347:1106, 1996Google Scholar
- 21.Boyum A: Isolation of leucocytes from human blood. A two phase system for removal of red cells with methylcellulose as erythrocyte-aggregating agents. Scand J Clin Invest 21(suppl 97):9–29, 1968Google Scholar
- 24.Nicoletti I, Migliorati G, Pagliacci MC: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Method 139:271–279, 1991Google Scholar
- 27.Dransfield I, Stocks SG, Haslett C: Regulation of cell adhesion molecule expression and function associated with neutrophil apoptosis. Blood 85:3246–3253, 1995Google Scholar
- 31.Allison MC, Dhillon AP, Lewis WG, Pounder RE: Pathogenesis of inflammatory bowel disease. In Inflammatory Bowel Disease. MC Allison, AP Dhillon, WG Lewis, RE Pounder (eds). London, Mosby, 1998, pp. 15–22.Google Scholar
- 32.Wright V, Amos R: Do drugs change the course of rheumatoid arthritis?. Br Med L 28:964–966, 1980Google Scholar